SCHEMBL3084944

SCHEMBL3084944

CCN(CC)C(=O)C(Cc1cnn(Cc2ccc(Cl)cc2)c1)C(=O)NS(=O)(=O)/C=C/c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
TSPO P30536 1/20 0.34
LMNA P02545 2/20 0.34
ALDH1A1 P00352 1/20 0.34
ACACB O00763 1/20 0.33
SCN9A Q15858 1/20 0.33
HTT P42858 1/20 0.33
F2 P00734 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GAA P10253 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KMT2A Q03164 1/20 0.33
HDAC2 Q92769 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3084946 1.00 CNR1 (0.35) CNR1CNR2KDM4EPOLBTSPO
SCHEMBL3103969 0.95 HDAC2 (0.36) POLBLMNAALDH1A1ACACBHTT
SCHEMBL3103975 0.95 HDAC2 (0.36) POLBLMNAALDH1A1ACACBHTT
SCHEMBL3090462 0.93 LMNA (0.42) KDM4EPOLBLMNAALDH1A1ACACB
SCHEMBL3090464 0.93 LMNA (0.42) KDM4EPOLBLMNAALDH1A1ACACB
SCHEMBL3084419 0.92 GAA (0.34) POLBLMNAALDH1A1ACACBHTT
SCHEMBL3084416 0.92 GAA (0.34) POLBLMNAALDH1A1ACACBHTT
SCHEMBL3092554 0.86 HDAC2 (0.35) POLBLMNAALDH1A1ACACBHTT
SCHEMBL3092559 0.86 HDAC2 (0.35) POLBLMNAALDH1A1ACACBHTT
SCHEMBL3093150 0.84 ACACB (0.33) KDM4EPOLBLMNAALDH1A1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 CNR1 1167/4885CNR2 907/4885KDM4E 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.